Investor Presentation Full Year 2017
Investor Presentation
Full year 2017
Slide 52
Key Novo Nordisk diabetes care products remain broadly
available in the USA
Value market shares of key
Novo Nordisk products in the USA
Value market
share
VictozaⓇ
TresibaⓇ
NovoLogⓇ
LevemirⓇ
% share of unrestricted market access of key
Novo Nordisk products in the USA
NovoLogⓇ
Market access
Unrestricted
VictozaⓇ
TresibaⓇ
LevemirⓇ
80%
60%
40%
20%
0%
Nov
2014
Source: IQVIA NSP Nov 2017;
100%
80%
60%
40%
20%
0%
Nov
2017
Note: Market shares: NovoLogⓇ: share of rapid acting insulin segment; LevemirⓇ: share of basal insulin
segment; TresibaⓇ share of basal insulin segment; VictozaⓇ: share of GLP-1 segment
changing
diabetes®
Aug
2014
Source: FingerTip Formulary bridge, Nov 2017 Nomenclature and Xponent PlanTrak,
Dec 2017; only considers bridged volume; excludes cash and mail order data;
Note: Unrestricted access excludes prior authorisation, step edits and other restrictions
LevemirⓇ access based on FlexTouch® Pen; NovoLog® access based on FlexPen®; only
considers bridged volume; TresibaⓇ launched in January 2016
Nov
2017
novo nordiskView entire presentation